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Abstract
The use of complementary and alternative medicine (CAM), including alternative therapies
(ALT) and natural health products (NHP) such as vitamin and herbal supplements, is increasingly
accepted in both the general population as well as in patients with mood and anxiety disorders.
The level of acceptance and use of CAM, however, is unknown among patients being treated for
psychotic disorders. Psychotic patients were surveyed about their use of and attitudes toward
CAM. Questions included basic demographic and socio-economic items as well as the lifetime
and 12-month use of CAM. Data were collected from June to October 2005. A sample of 172
participants representing 8.4% of the total eligible population of the outpatient clinics within the
Schizophrenia Program at the Centre for Addiction and Mental Health in Toronto Canada
completed the survey. Considering all forms of CAM, the lifetime and 12-month prevalence rate
were 88% and 68%, respectively. The use and perceived safety of CAM by this population is
similar to that reported by the general population. Clinical and public health implications of these
findings are discussed.
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Introduction  
Schizophrenia is associated with severe social and cognitive dysfunction (Lewis 
& Moghaddam, 2006; Stanghellini & Ballerini, 2007).  Conventional treatments 
for schizophrenia including the use of antipsychotic medications (Kapur & 
Mamo, 2003)  may not eliminate all symptoms and have the potential for adverse 
effects (Stahl & Buckley, 2007).  Earlier research has suggested that patients with 
psychotic disorders may turn to complementary and alternative medicine (CAM), 
defined as products and practices that are not considered part of conventional 
medical practice (National Institutes of Health, 2009).  Previous studies suggest 
that CAM is primarily used in addition to conventional therapy (Demling et al., 
2002) by individuals seeking to improve their quality of life, (Rickhi et al., 2003) 
and to restore hope that their distress may be reduced if not eliminated (Murray & 
Rubel, 1992).  However, the clinical benefits of CAM for psychotic symptoms are 
either unsubstantiated (Ping et al., 1997) or have been refuted (Chen et al., 1997; 
Rathbone et al., 2005; Zhang & Zhou, ; Zhang et al., 2001).     
High prevalence of CAM use has been reported in North Americans and 
Europeans, with recent trends toward increasing use (Assion et al., 2007; Demling 
et al., 2002; Druss & Rosenheck, 2000; Eisenberg et al., 1998; Fisher & Ward, 
1994; Health Canada, 2005, 2007; Ramsay et al., 1999; Statistic Canada, 2003; 
Unutzer et al., 2000).  For example, the Canadian Community Health Survey in 
2003, reported that 20% of Canadians aged 12 or older had visited at least one 
type of CAM provider such as a chiropractor or naturopathic practitioner 
(Statistics Canada, 2003).  More recently, results from the Natural Health 
Products Directorate of Health Canada survey (2005) estimated that 71% of 
Canadians have used natural health products (NHP) at some time in their lives 
(Health Canada, 2005).  These findings are consistent with the results of 
epidemiological surveys from other countries (Demling et al., 2002; Druss & 
Rosenheck, 2000; Eisenberg et al., 1998; Fisher & Ward, 1994; Health Canada, 
2005; Ramsay et al., 1999; The National Center for Complementary and 
Alternative Medicine; Unutzer et al., 2000).   
The literature suggests that patients suffering from mental health problems 
may be especially high users of CAM.  A recent Canadian study showed that 
approximately 70% of people attending a complementary therapy clinic reported 
suffering from a psychiatric condition (anxiety & depression) using DSM-III-R 
criteria (American Psychiatric Association, 1994; Rickhi et al., 2003).  A high 
prevalence of CAM use by individuals with anxiety and depressive disorders has 
also been found in national surveys of both American and British populations 
(Chen et al., 1997; National Institutes of Health, 2007; Ping et al., 1997; Rathbone 
et al., 2005; Zhang et al., 2001).  In a survey of CAM use in psychiatric inpatients 
in Germany, the number of patients with schizophrenia who reported CAM use 
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was identical to those with depression (Assion et al., 2007).  An analysis of the 
National Comorbidity Survey-Replication in the United States  reported a rate of 
31.1 % of unverified CAM use among persons with psychiatric care needs.  In 
Canada, where conventional therapies are paid for by the state, it is not clear if 
similarly high numbers of patients with primary psychotic disorders will seek 
CAM therapies for which they must pay directly. 
In Canada, NHPs are easily available in community pharmacies and health 
food stores and are marketed extensively in the media.  Although a number of 
regulatory measures have been instituted to ensure adequate safety standards in 
the manufacturing and labeling of these products, the extent of patients’ 
awareness of the true effects and safety of these therapeutic modalities is 
unknown for patients with severe mental illness (Health Canada, 2005). Social 
and cognitive disability in patients with primary psychotic disorders may increase 
their vulnerability to advertisements of the purported therapeutic benefits of 
CAM.  Other factors such as gender and underlying belief systems are also likely 
to contribute to the use of CAM (Chiu et al., 2005).  We therefore conducted a 
survey of ambulatory patients with schizophrenia and related primary psychotic 
disorders followed at an inner city psychiatric hospital in Toronto to determine the 
prevalence and attitudes toward the safety and benefits of CAM.   
The primary objective of this paper is to report the prevalence (lifetime 
and 12 months) of diverse CAM modalities including NHP (natural health 
products) such as herbal medicines excluding vitamins and minerals); ALT 
(alternate therapies such as yoga or meditation); VIT (vitamins and minerals); and 
CMP (visits to complementary medicine practitioners) in ambulatory patients 
with schizophrenia and related primary psychotic disorders followed at an inner 
city psychiatric hospital in Toronto.  We hypothesize that the rate of use in our 
sample would be lower than the rates of CAM use found in community samples 
of the general population.  The second objective of the paper is to report on our 
examination of the perceived benefits and safety of the CAM and “conventional 
medical care” received directly from doctors.  We hypothesized that current and 
past users of CAM would report more perceived benefits and perceive CAM as 
safer than those who had never used CAM.  
Methods 
The study was approved by the Research Ethics Board of the Centre for Addiction 
and Mental Health.  This study used an interviewer-assisted paper survey 
instrument to measure the use of, and attitudes toward, CAM in patients with 
psychotic disorders.  The survey consisted of basic demographic and socio 
economic items, the lifetime and 12-month use of CAM, including CAM 
practitioners (CMP) and ALT, VIT and NHP. VIT were assessed as a separate 
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category from other NHP (such as herbal medicines, essential fatty acids, 
probiotics and homeopathic medicines) because several vitamins are routinely 
used by physicians to treat specific medical conditions - thus the use of these 
vitamins could not be considered CAM.  For example, Vitamin E has been used 
for tardive dyskinesia (Arvindakshan et al., 2003), and vitamin B1 (Lerner et al., 
2004) is often administered to prevent Wernike’s encephalopathy in persons 
experiencing withdrawal from alcohol.  In this study, CAM use was defined as 
consulting a CMP, using ALT, VIT or NHP.  A list of each was provided to the 
respondents along with an opportunity to add additional items in any category.  
CAM practitioners (CMP) included aboriginal healers, acupuncturists, 
Ayurvedic/Indian Medicine practitioners, chiropractors, doctors of 
complementary medicine, herbalist, homeopathic practitioners, and massage 
therapist.  ALT included biofeedback, homeopathy, hypnosis, meditation or 
relaxation techniques, tai chi, traditional Chinese medicine, and yoga.  VIT 
included vitamin A or beta carotene, vitamin B, vitamin C, vitamin E, calcium, 
magnesium or multivitamins.  Typically NHP encompass a wide range of 
products such as herbal remedies, vitamins, minerals and other forms of 
supplementation.  In this study however, NHP were limited to those commonly 
used in psychiatric conditions which were presented in a list to the respondents: 
chamomile, cod liver oil, echinacea, evening primrose oil, garlic, ginkgo, ginseng, 
glucosamine, kava kava, palmetto, valerian, and St. John’s wort. (Table 2) 
The survey instrument was adapted from a survey that was developed and 
used to assess CAM use among a sample of cancer patients (Boon et al., 2003).  
Minor modifications were made to this survey to include items that were more 
applicable to patients being treated for psychotic disorders.  The modifications 
were based on the findings from a qualitative pilot study of schizophrenic 
outpatients' use of and attitudes towards CAM and NHPs that was conducted in 
2004 (Personal communication, Dr. Mamo). 
Ambulatory patients enrolled in the schizophrenia program at the Centre 
for Addiction & Mental Health - CAMH (an inner city hospital affiliated with the 
University of Toronto) who were considered by the treating team to be clinically 
stable and able to tolerate a brief survey were eligible to participate in the study. 
The schizophrenia program at CAMH provides ambulatory care to more than 
3000 patients, which is approximately 25 % of patients suffering from primary 
psychotic disorders in Toronto.  Given the tertiary care nature of the Centre, many 
patients followed by the program would likely have failed routine community-
based management.  Diagnosis of schizophrenia was not confirmed by the study 
interviewers and no direct clinical input from the treating psychiatrists was sought 
as part of the survey.  Subjects were either self-referred in response to posted 
advertisements at the Centre, or referred by their case-workers.  In all cases, a 
trained research assistant facilitated the completion of the survey.  For this study, 
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participants received a token honorarium of $10 for each hour spent completing 
the survey. 
To determine the perceived benefits and safety of conventional medicine, 
participants were asked to rate their experiences with “conventional medical 
treatments” by indicating their perceptions of the “truth’ of a set of statements that 
describe possible benefits and safety issues. Respondents indicated their opinions 
on a five point scale, ranging from “not at all true” to “very true”.  However, due 
to few responses with extreme choices, responses with “not at all true” and “not 
very true” were assigned a value of zero, while “fairly true” and “very true”  were 
assigned a value of 2.  The neutral (mid-point) category was coded as 1.  The 
scales of perceived benefit and safety of conventional medicine were computed as 
the sum of the three item scores.  The internal consistency (as measured by 
Cronbach's alpha coefficients) of the three-item scales of perceived benefit and 
safety were 0.65 and 0.36 respectively.  All respondents, irrespective of their 
previous use of CAM, were asked to rate the same set of statements regarding 
their experiences with NHPs.  Perceived benefits and safety of NHPs were 
computed following the same operations used to rate the benefits and safety of 
conventional medicine and the internal consistency of the three item scales of 
perceived benefit and safety of CAM were 0.73 and 0.56 respectively. 
Results 
Table 1. Patient demographics (N-=172) and prevalence (%). 
Demographic Factors
Sex (%) Income
Male 72.7 Annual income
Female 27.3 <10,000 Cdn $ 61.0 % 
Race >10,000 Cdn $ 39.0 % 
Caucasian/European 58.7  Source of Income
Others 41.3 Ontario Disability 
Support Program 
76.7 % 
Country of Birth 
Canada 63.4 Part time Employment 4.1 % 
Outside Canada 36.6 Full time Employment 3.5 % 
Marital Status Unknown 15.7 % 
Never married /single 85.5
Unknown 14.5 
Table 1 summarises the demographics of the participants.  In total, 172 patients 
participated in the study (73% were male; mean age  SD = 41 + 12.5 years, 
range = 19-64 years), with a self-reported diagnosis of schizophrenia (82%), 
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schizoaffective disorder (7.6%), psychosis not otherwise specified (4.1%), bipolar 
disorder (1.2%), and major depression (0.6%).  The duration of illness ranged 
from less than a year to 25 years.  The overrepresentation of male participants is 
consistent with the 3:1 ratio of males to females in the Schizophrenia Program at 
the Centre for Addiction and Mental Health.  Most respondents (85.5%) were 
single and had never married, less than half (44.8%) of the participants had 
attained a high school diploma.  61% of participants were predominantly of lower 
socioeconomic status earning less than $10,000 in 2004.  A similar trend was 
found with respect to household income, with 50% of participants reporting 
annual household incomes of less than $10, 000.  Only a small fraction of the 
sample was employed with either part time (4.1%) or full time (3.5%) 
employment, and more than three quarters of respondents (76.7%) identified the 
allowance from the Ontario Disability Support Program (ODSP) as their main 
source of income.  The majority of the respondents were Canadian born (63.4%) 
and of Caucasian descent.  These figures suggest that the representation of 
immigrants in our sample (36.6%) was lower than the proportion of immigrants in 
the Greater Toronto Area (45.7%) (Chui et al., 2007), whereas the proportion of 
visible minority (41.3%) was representative of that in the Greater Toronto Area 
42.9%) (Statistic Canada, 2008).  
The majority of participants (88.4%) reported using some type of CAM at 
least once during their lifetime, and 68.0% reported having used CAM during the 
last 12 months. Only 48% of participants reported disclosing their use of CAM to 
their psychiatrists or case managers, and only 42 % reported their use of CAM to 
their family physicians.   
Table 2 lists the lifetime and past year prevalence of the different CAM 
dimensions (CMP, ALT, VIT and NHP) in our population.  The lifetime 
prevalence of visiting a CAM practitioner was 40.7%.  The most commonly 
reported practitioners utilized were chiropractors (20.9%), followed by massage 
therapists (11.6%), and acupuncturists (9.9%).  Within the past year, 16.9% of 
participants visited at least one CAM practitioner.   
The lifetime prevalence of ALT use was 52.9%.  Meditation/relaxation 
techniques were the most commonly reported therapies used (39.5%), followed by 
yoga (23.3%), and tai chi (11.6%).  Within the past year, 33.3% of participants 
reported use of at least one ALT.  
The lifetime prevalence of VIT intake was 70.3%.  The most commonly 
used vitamin supplement was the multivitamin (54.1%), followed by vitamin C 
(32.0%) and calcium supplements (22.1%), vitamin E (15.7%), and vitamin B 
(14.5%).  Within the past year, 48.3% of participants used at least one vitamin and 
mineral supplement.  
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Table 2. Lifetime and past year prevalence of complementary and alternative 
medicine (CAM) dimensions. 
CAM 
Dimensions 
 Lifetime  
Prevalence 
(%) 
Past Year 
Prevalence  
( %) 
CAM 
Practitioners 
Acupuncturist/Traditional Chinese 
Ayurvedic/Indian Medicine 
Aboriginal Healer 
Chiropractor 
Doctor of Complementary Medicine 
Herbalist 
Homeopathic practitioner 
Massage Therapist 
Naturopathic practitioner 
Reflexologist 
Reiki Healer 
Therapeutic-touch  
practitioners 
9.9 
1.2 
4.7 
20.9 
4.7 
5.8 
4.1 
11.6 
4.7 
2.9 
4.1 
2.3 
3.9 
0.7 
2.8 
8.7 
2.9 
3.5 
3.4 
4.7 
3.5 
1.7 
1.7 
0.6 
Alternative 
Therapies 
Biofeedback 
Homeopathy 
Hypnosis 
Meditation or relaxation techniques 
Tai Chi 
Traditional Chinese Medicine 
Yoga 
2.3 
4.7 
5.8 
39.5 
11.6 
3.5 
23.3 
1.7 
3.5 
0.6 
25 
4.1 
2.9 
11.6 
Vitamin and 
Mineral 
Supplements 
Vitamin A or Beta carotene 
Vitamin B* 
Vitamin C 
Vitamin E* 
Calcium 
Magnesium 
Multi-vitamin 
8.7 
14.5 
32.0 
15.7 
22.1 
9.3 
54.1 
7.5 
8.9 
20.3 
11.0 
18.0 
8.3 
36.0 
Other NHPs Chamomile 
Cod Liver Oil 
Echinacea 
Evening Primrose Oil 
Garlic 
Ginkgo* 
Ginseng 
Glucosamine Sulphate 
Kava Kava 
M. Valerian 
St. John’s Wort* 
Saw Palmetto 
34.3 
30.8 
16.9 
5.2 
15.7 
7.6 
27.3 
5.2 
1.2 
4.7 
8.7 
1.7 
16.9 
5.2 
9.3 
2.3 
8.7 
3.5 
11.0 
3.5 
0.0 
1.2 
1.7 
0.6 
* Vitamins and supplements and NHPs that have been reported to be used in the treatment of 
psychiatric disorders. 
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The lifetime use of NHPs was 62.8%.  The most commonly used NHPs 
were: chamomile (34.3%), cod liver oil (30.8%), ginseng (27.3%), echinacea 
(16.9%), and garlic (15.7%).  Within the past year, 36% of participants reportedly 
used at least one NHP.  
Table 3. Comparison of users and non-users of Natural Health Products (NHP), 
alternative therapies (ALT), vitamin and mineral supplement products (VIT), 
complementary and alternative medicine practitioners (CMP) users on perceived 
benefits and safety of NHP and conventional medicines. 
 BENEFIT SAFETY 
Benefit of 
CAM 
Benefit of  
 Conventional 
Medicine 
Safety of   
CAM 
Safety of 
 Conventional  
Medicine 
N 
H 
P 
Lifetime User 4.87 (1.44) 4.15 (1.91) 4.43 (1.40) 1.25 (1.28)
Non- user 3.86 (1.75)  4.34 (1.69) 2.09 (1.18)  1.86  (1.22)
P value <0.001 0.499 <0.001 0.002 
Past 
12 month  
Use 
User 5.35 (1.03) 4.05 (1.03) 2.39 (1.49) 1.13   (1.34)
Non- user 4.01 (1.72) 4.32 (1.76) 2.25 (1.24) 1.67 (1.22)
P value <0.001  0.354 0.532 0.007 
A 
L 
T 
Lifetime User  4.74 (1.61) 4.16 (1.87) 2.11 (1.45) 1.16 (1.26) 
Non- user 4.22 (1.63)  4.28 (1.79)  2.52 (1.15) 1.83  (1.23)
P value 0.039 0.671 0.044 0.001 
Past  
12 month  
Use 
User 4.96 (1.63)  4.16  (1.85) 2.09 (1.49) 0.93 (1.34) 
Non- user 4.26 (1.60) 4.25  (1.82) 2.41 (1.23)  1.73  (1.19) 
P value 0.007 0.751 0.131 <0.001 
V 
I 
T 
Lifetime User 4.69 (1.53)   4.16 (1.88)   2.21 (1.41)  1.36  (1.25) 
Non- user  4.09 (1.78)   4.37 (1.71)   2.53 (1.10) 1.75  (1.34) 
P value   0.013   0.482   0.146   0.076 
Past  
12 month  
Use 
User 4.88 (1.50)   4.12 (1.86)   2.27 (1.45)   1.33 (1.33) 
Non- user  4.13 (1.68)   4.31 (1.81)   2.34 (1.21) 1.62 (1.24) 
P value 0 .003  0.488   0.724 0.136 
C 
M 
P 
Lifetime User   4.63 (1.75)   4.19  (1.88) 2.44 (1.40)   1.31 (1.29) 
Non- user   4.40 (1.55)   4.25 (1.80)  2.21 (1.28) 1.59 (1.28) 
P value   0.373  0 .835  0 .252 0  .171 
Past  
12 month  
Use 
User   4.90 (1.54)     4.34 (2.02)   2.48 (1.50)   0.96  (1.22) 
Non- user   4.41 (1.65)   4.20 (1.79)   2.27 (1.29)   1.59  (1.27) 
P value  0 .147 0.690  0 .424 0 .012 
NHP: Chamomile, Ginseng, Echinacea, Garlic, Cod liver oil, Ginkgo, Glucosamine, Lecithin, 
Kava kava, St. John’s wort, Valerian, Saw palmetto, Evening primrose oil.ALT: 
Meditation/relaxation techniques/ visualization/ imagery, Yoga, Tai chi, Homeopathy, Traditional 
Chinese Medicine, Biofeedback, Hypnosis.VIT: Multivitamin; Vitamin (A, B, C, E); Calcium; 
Magnesium.CMP: Chiropractor, Massage Therapist, Acupuncturist, Ayurvedic Practitioner, 
Herbalist, Naturopath, Homeopath, Reflexologist, Reiki Healer, Aboriginal Healer, Therapeutic 
Touch Practitioner, Doctor practicing complementary and alternative medicine. 
Table 3 compares the perceived benefits and safety of CAM and 
conventional medicines by users and non-users of NHP, ALT, VIT, CMP with 
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respect to their perceptions of the benefits and safety of NHP and conventional 
medicines.  Lifetime users of NHP scored significantly higher on their perception 
of both the benefits and the safety of CAM (p<0.001; p<0.001), and scored 
significantly lower on their perception of safety for conventional medicine 
compared to lifetime non-users of NHP (p=0.007).  However, the use of NHP had 
no impact on the perceived benefits of conventional medicine.  These results were 
similar for subjects using NHP within the last12 months.  Lifetime users of ALT 
attributed greater benefit to CAM than lifetime non-users of ALT (p = 0.39) but 
lifetime users of ALT also perceived NHP (not including vitamins and minerals) 
to be less safe than non-users (p = 0.44) (i.e., users of ALT were more likely to 
recognize the potential for side effects from CAM.  Use of CAM therapies was 
not associated with a difference in perceived benefit of conventional medicine (p 
= 0.671).  We found no difference in the perceptions of benefit and safety of 
CAM between those that reported visits to CMP and those that did not, though 
those reporting recent visits to CMP were more likely to attribute adverse effects 
to conventional medicine.  Participants who reported the use of VIT rated the 
attributes of CAM as more beneficial than non-users of VIT.  No differences were 
found between users and non-users of VIT with respect to views about the safety 
of CAM or the benefits and safety of conventional medicine.   
Discussion 
This is the first study to report quantitative data estimating the lifetime and 12-
month prevalence of use of CAM modalities and subjective assessments of the 
perceived safety and benefits of these modalities and products in patients with 
schizophrenia and related primary psychotic disorders.  The principle finding 
from this survey is a very high lifetime prevalence of 88% of these therapies in 
patients with a primary psychotic disorder, which is not different from data 
derived from larger epidemiological surveys within the Canadian population.  The 
pattern of use was also similar to that reported in the general population: the most 
commonly visited CAM practitioner is the chiropractor (Canadian population: 
40%; our survey: 20.9%) (Esmail, 2007) and the most commonly used CAM 
therapy is meditation/relaxation (Canadian population: 20%; our survey 25%) 
(Esmail, 2007).  Similarly, vitamins are the most frequently used  in both 
populations (Canadian population: 57.%, our survey: 70.3%) (Health Canada, 
2005).    
These findings were surprising for a number of reasons.  First, surveys of 
the general population have shown that individuals with higher incomes or more 
formal education are more likely to use complementary and alternative therapies 
including NHP (Fisher & Ward, 1994; National Institutes of Health, 2007).  In our 
study, the highest education attained by most of the participants was a high school 
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diploma, and their annual income that was less than $10,000 - thus we expected 
lower use than the general population.  Studies of other groups of individuals with 
mental illness have found rates of CAM use that are similar both to the general 
public and to our findings.  For example, in a self-report survey involving 
inpatients with mental illness, 63% used at least one CAM modality, and the 
majority of these patients were high school graduates (Ramsay et al, 1999).  In 
another study involving a community mental health service, high use of CAM 
was found among Chinese Americans who were employed and had completed 
high school education(Fang & Schinke, 2007).  Identical findings were found 
with psychiatric inpatients in Germany (Assion et al., 2007).  Finally, we found a 
high rate of use of CAM in our sample which was predominantly male (72%).  
All of these findings challenge the assumption that CAM use is concentrated in 
females with high incomes and education.  
Persons suffering from schizophrenia and related psychotic disorders tend 
to suffer from decreased motivation as part of their illness and would therefore be 
expected to be less proactive in exploring alternative therapeutic modalities.  In 
contrast, patients with mood and anxiety disorders are known to be more likely to 
engage in help seeking behaviours (Assion et al., 2007; National Center for 
Complementary and Alternative Medicine, 2007; Statistic Canada, 2003).  Our 
finding of a high prevalence of all types of CAM (88%) and NHP (63%) use in 
this population was therefore unexpected.  
Why would patients with schizophrenia and related psychotic disorders 
seek out CAM despite low incomes, poor education, and the presence of negative 
symptoms such as apathy and amotivation?  Possible explanations to account for 
this high use include the perceived lack of efficacy in conventional medications in 
decreasing distress experienced in their illnesses (Assion et al., 2007) and the use 
of NHPs to counter the side effects of the prescribed psychiatric medications 
(Fang & Schinke, 2007).  NHPs may also be used for conditions unrelated to their 
psychiatric diagnoses (e.g., echinacea for the common cold (Yale & Liu, 2004) or 
glucosamine for osteoarthtiritis (Christgau et al., 2004).  It is unclear in our study 
whether NHPs were being used for a psychiatric disorder or for other reasons 
including side effects from psychiatric medications.  On the other hand, the high 
use may be interpreted as a way of patients taking some control over their 
treatment that they often perceive as imposed by their clinicians given a decreased 
level of insight associated with schizophrenia.  CAM use could also resonate with 
their philosophical values and beliefs (Assion et al., 2007; National Center for 
Complementary and Alternative Medicine, 2007).  This study was not designed to 
elucidate the motivation behind these behaviours. 
We are concerned with our finding of a high level of reluctance on the part 
of participants to disclose their use of CAM to their health care providers, even if 
this is consistent with published results from the general population (Assion et al., 
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2007; Chen et al., 1997; National Center for Complementary and Alternative 
Medicine, 2007).  Although the reasons are unknown, previous qualitative field 
studies used as pilot data for this study (personal communication, Dr. Mamo) 
suggest that this population may not perceive conventional medical practitioners 
to be in a position to advise them on their use of CAM.  The public health 
significance of this observation is self evident in view of the potential adverse 
effects and interactions with prescription medications.  Although CAM has a 
reputation for being natural (which, for most lay persons is synonymous with 
safe), this assumption is incorrect.  For example, kava kava, a naturally occurring 
antianxiety agent has been withdrawn as it has been associated with 
hepatotoxicity (Fang & Schinke, 2007).  Wernike et al. (2006) reviewed 2700 
studies for 20 remedies such as ginkgo and St. John’s wort that may be used to 
alleviate psychiatric ailments (American Psychiatric Association, 1994; Natural 
Standard, 2007).  The safety of these remedies for the treatment of psychiatric 
disorders has not been established and more systematic clinical trials are clearly 
needed to establish the safety and therapeutic efficacy of these products(American 
Psychiatric Association, 1994; Natural Standard, 2007). 
This leads to a discussion about concerns regarding the potential 
vulnerability of this population.  Partial response to antipsychotic treatment is 
very common, leaving clients with distressing residual symptoms (Alphs, 2006; 
Stahl & Buckley, 2007).  Schmid and Brunisholz (2007) found that the motivation 
for using CAM included personal interest and the influence of friends, family and 
acquaintances.  The cognitive deficits (Rajji & Mulsant, 2008) prevalent in this 
population may make it difficult for many of them to critically assess the safety 
and effectiveness of CAM.  Hence this population may be vulnerable to the 
marketing strategies used to promote CAM modalities and the potentially 
misleading influence of friends and family members. This suggests an urgency to 
further study the reasons for use of CAM in this population. 
Based on the results of this study, clinicians responsible for the care of 
patients with schizophrenia and related psychotic disorders should consider 
including an assessment of current and past CAM use in their routine medical 
workups.  A non-judgmental approach and genuine interest in the use of CAM 
may also have the added benefit of enhancing the therapeutic alliance between 
patient and clinician.  Given the complexities of drug interactions, a discussion of 
the potential risk of concomitant use of NHP with psychotropic agents is 
recommended, and referral to a pharmacist may be indicated if the clinician lacks 
expertise in drug NHP interactions.  Although some patients may choose to use 
NHPs as alternatives to conventional treatment, many decide to use them in 
addition to prescribed medications.  In contrast to the reported adverse effects 
from NHP use in epidemiological studies, (Fisher & Ward, 1994) the majority of 
respondents to our survey reported experiencing side effects from their 
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prescription medications instead of NHPs.  Thus clinicians would be wise to heed 
their clients’ perceptions and subjective experiences of both prescription 
medications and NHP - not only would this have implications for safe prescribing 
but it would also likely have beneficial effects on medication adherence.  This is 
especially important since the participants in this study perceived the use of NHP 
positively, a finding that reflects the views of the general population (Fisher & 
Ward, 1994; National Institutes of Health, 2007).  Users of NHP also 
acknowledge the benefits of conventional medication. This is important since 
many conventional clinicians associate NHP use with a belief that conventional 
medicine lacks its purported benefits – our results refute this stereotype.  It is 
encouraging to note that in our sample, users of NHP were more likely than non 
users of NHPs to recognize and acknowledge the adverse effects of NHP.  Not 
surprisingly, lifetime users of CAM attribute greater benefit to NHP than non 
users, but they were more likely to acknowledge potential adverse effects from 
NHPs. 
The results of the study need to be interpreted within the context of a 
number of limitations of the study design.  While it would have been ideal to 
randomly sample the population, our pilot work suggested that this was not 
feasible.  This population is known to have deficits in cognition and executive 
functioning (Rajji & Mulsant, 2008) and to be typically unable to adhere to 
appointments, making it difficult to reach them using common population survey 
methods (e.g., telephone, mailed or internet-based surveys).  Thus our study used 
a convenience sample of participants who either self-referred after seeing posters 
or accepted a referral from a clinician.  This sampling incurs the risk of an 
ascertainment bias, potentially inflating the prevalence of CAM use in this 
population. Furthermore, some VIT such as vitamin E (Arvindakshan et al., 2003) 
and B (Lerner et al., 2004) may have been prescribed for conditions such as 
tardive dyskinesia, and therefore represent a more conventional therapy.  In 
addition, the study design did not take into account the participants’ mental states 
at the time of completion of the survey.  It is possible that this may have been an 
important hidden factor in the interpretation of the results.  Finally, the survey 
was not designed to elucidate the motivation and reasons behind the use of CAM, 
limiting our ability to derive an explanatory model for the high CAM use 
observed in the study. 
 Notwithstanding these limitations, this study reports on the prevalence of 
CAM use in the severely mentally ill within the Schizophrenia program at the 
Centre of Addiction and Mental Health.  Contrary to our expectation, we found 
that the prevalence and attitudes towards CAM use and conventional medicine to 
be similar to published reports in the general population.  The findings highlight 
the importance of including a review of CAM use in routine clinical practice in 
patients with severe mental illness, and dispel a number of myths and stereotypes 
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pertaining to the use of CAM in this population.  This study also highlights the 
apparent lack of communication between clinicians and patients about CAM use 
and our lack of knowledge about mental health clinicians’ attitudes toward CAM.  
Future studies to explore the motivation underlying the use of the respective CAM 
modalities are needed to provide an explanatory model for these observations.   
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